Synapsoft logo
AI Insights from Disclosures
Searching...
GI Innovation Inc. 358570
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
GI Innovation Inc. is a biotechnology company that researches and develops next-generation immunotherapies based on fusion proteins, holding a variety of new immunotherapy drug pipelines, including its core pipeline assets GI-101/GI-102, immuno-oncology drugs, and GI-301, an allergy treatment. The company is composed of experts in biopharmaceutical R&D and technology commercialization, including basic scientists in the pharmaceutical/bio field, process development specialists, and clinical development and technology transfer specialists, and on this basis it has secured platform technology for discovering new fusion protein drugs, its own process development technology, and clinical development capabilities based on unmet medical needs in target markets.
Representative Director 장명호, 홍준호(각자대표이사)
Founded July 19, 2017
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 14521-0021112
Business number 682-86-00771
Phone Number 02-404-2003
Fax Number 02-2054-8609
Company Address 167 Songpa-daero, Songpa-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant